EA201790932A1 - Дозировка и введение нефукозилированных анти-cd40 антител - Google Patents

Дозировка и введение нефукозилированных анти-cd40 антител

Info

Publication number
EA201790932A1
EA201790932A1 EA201790932A EA201790932A EA201790932A1 EA 201790932 A1 EA201790932 A1 EA 201790932A1 EA 201790932 A EA201790932 A EA 201790932A EA 201790932 A EA201790932 A EA 201790932A EA 201790932 A1 EA201790932 A1 EA 201790932A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
nonfuculated
dosage
administration
unfucosylated
Prior art date
Application number
EA201790932A
Other languages
English (en)
Other versions
EA036498B1 (ru
Inventor
Шира Гардай
Чэ-Леунг Ло
Стэнфорд Пенг
Цзин Ян
Хейли Нефф-Лафорд
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55858352&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790932(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Publication of EA201790932A1 publication Critical patent/EA201790932A1/ru
Publication of EA036498B1 publication Critical patent/EA036498B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0009—Making of catheters or other medical or surgical tubes
    • A61M25/0012—Making of catheters or other medical or surgical tubes with embedded structures, e.g. coils, braids, meshes, strands or radiopaque coils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/002—Packages specially adapted therefor ; catheter kit packages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Настоящее изобретение относится к способам применения нефукозилированного анти-CD40 антитела для лечения рака и хронических инфекционных заболеваний.
EA201790932A 2014-10-29 2015-10-29 Дозировка и введение нефукозилированных анти-cd40 антител EA036498B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072031P 2014-10-29 2014-10-29
US201562134955P 2015-03-18 2015-03-18
PCT/US2015/058108 WO2016069919A1 (en) 2014-10-29 2015-10-29 Dosage and administration of non-fucosylated anti-cd40 antibodies

Publications (2)

Publication Number Publication Date
EA201790932A1 true EA201790932A1 (ru) 2017-08-31
EA036498B1 EA036498B1 (ru) 2020-11-17

Family

ID=55858352

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790932A EA036498B1 (ru) 2014-10-29 2015-10-29 Дозировка и введение нефукозилированных анти-cd40 антител

Country Status (22)

Country Link
US (8) US11213584B2 (ru)
EP (2) EP3831847A1 (ru)
JP (5) JP6691113B2 (ru)
KR (1) KR20170072884A (ru)
CN (2) CN114522228A (ru)
AU (2) AU2015339128C1 (ru)
BR (1) BR112017008959A2 (ru)
CA (1) CA2963720A1 (ru)
CY (1) CY1124033T1 (ru)
DK (1) DK3212230T3 (ru)
EA (1) EA036498B1 (ru)
ES (1) ES2864756T3 (ru)
HK (1) HK1243328A1 (ru)
HU (1) HUE054075T2 (ru)
IL (2) IL299075A (ru)
MX (1) MX2017005152A (ru)
PL (1) PL3212230T3 (ru)
PT (1) PT3212230T (ru)
SG (2) SG10201913099YA (ru)
SI (1) SI3212230T1 (ru)
WO (1) WO2016069919A1 (ru)
ZA (2) ZA201702347B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913099YA (en) * 2014-10-29 2020-02-27 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
US20210001032A1 (en) * 2015-03-27 2021-01-07 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
WO2017143069A1 (en) 2016-02-17 2017-08-24 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
TW201806972A (zh) 2016-05-27 2018-03-01 美商艾伯維生物醫療股份有限公司 雙特異性結合蛋白
US10519243B2 (en) 2016-05-27 2019-12-31 Abbvie Biotherapeutics Inc. Anti-CD40 antibodies
WO2018088850A2 (ko) 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
MX2020005463A (es) 2017-12-01 2020-09-07 Seattle Genetics Inc Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
KR20210038839A (ko) * 2018-03-13 2021-04-08 히버셀, 인크. 베타 글루칸 및 cd40 효능제 조합 면역요법
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MX2021002002A (es) 2018-08-23 2021-05-31 Seagen Inc Anticuerpos anti inmunorreceptor de celulas t con dominios ig y motivo inhibidor inmunorreceptor basado en tirosina (tigit).
AU2019383548A1 (en) 2018-11-23 2021-06-24 Strike Pharma Ab Bi-specific conjugates
FR3089597B1 (fr) 2018-12-06 2020-11-20 Gaztransport Et Technigaz Cuve étanche et thermiquement isolante
CN113438951A (zh) * 2018-12-19 2021-09-24 西根股份有限公司 抗体的受控岩藻糖基化
EP3941480A4 (en) * 2019-03-18 2023-04-26 Score Pharma, Inc. FUCOSYLATION INHIBITION COMPOUNDS AND METHODS OF USE THEREOF
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
US20230139944A1 (en) * 2019-06-21 2023-05-04 Board Of Regents, The University Of Texas System Targeting alpha3beta1 integrin for treatment of cancer and other diseases
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
WO2022072523A1 (en) 2020-09-30 2022-04-07 Seagen Inc. Uveal melanoma treatment using sea-cd40
IL302402A (en) 2020-11-08 2023-06-01 Seagen Inc Combined treatment
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
TW202314247A (zh) 2021-05-25 2023-04-01 美商思進公司 量化抗cd40抗體之方法
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023010080A1 (en) 2021-07-30 2023-02-02 Seagen Inc. Treatment for cancer
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU6934600A (en) 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
WO2001024823A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
CA2406961A1 (en) 2000-04-19 2002-02-14 Tanox, Inc. Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
EP2011802A3 (en) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
CA2609269C (en) * 2005-05-26 2014-08-05 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
JP2009518441A (ja) * 2005-12-09 2009-05-07 シアトル ジェネティクス，インコーポレーテッド Ｃｄ４０結合剤の使用方法
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
JP5730576B2 (ja) 2007-11-07 2015-06-10 ジェネンテック， インコーポレイテッド 抗ｃｄ４０抗体による治療に対するｂ細胞リンパ腫の応答性を評価するための方法及び組成物
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
CA2975228C (en) * 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
US20130071403A1 (en) * 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
SG10201913099YA (en) * 2014-10-29 2020-02-27 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies

Also Published As

Publication number Publication date
IL251552B1 (en) 2023-01-01
JP2020200343A (ja) 2020-12-17
EP3212230A4 (en) 2018-06-20
CA2963720A1 (en) 2016-05-06
JP6833080B2 (ja) 2021-02-24
IL251552A0 (en) 2017-05-29
WO2016069919A1 (en) 2016-05-06
JP2020050677A (ja) 2020-04-02
PL3212230T3 (pl) 2021-07-26
US20240075135A1 (en) 2024-03-07
EP3212230B1 (en) 2021-01-20
AU2015339128A1 (en) 2017-04-20
US20220265822A1 (en) 2022-08-25
JP6691113B2 (ja) 2020-04-28
US11202827B2 (en) 2021-12-21
JP7165166B2 (ja) 2022-11-02
US20240075134A1 (en) 2024-03-07
US20230201344A1 (en) 2023-06-29
US20230201343A1 (en) 2023-06-29
US11213584B2 (en) 2022-01-04
AU2015339128C1 (en) 2021-12-16
AU2021202407A1 (en) 2021-05-20
JP2023126406A (ja) 2023-09-07
KR20170072884A (ko) 2017-06-27
IL299075A (en) 2023-02-01
AU2015339128B2 (en) 2021-01-21
JP2021088609A (ja) 2021-06-10
IL251552B2 (en) 2023-05-01
ES2864756T3 (es) 2021-10-14
MX2017005152A (es) 2017-08-04
ZA202102219B (en) 2022-10-26
CN114522228A (zh) 2022-05-24
DK3212230T3 (da) 2021-04-19
HUE054075T2 (hu) 2021-08-30
JP2017533909A (ja) 2017-11-16
CN107073118A (zh) 2017-08-18
US20220249662A1 (en) 2022-08-11
SG11201702598XA (en) 2017-05-30
EA036498B1 (ru) 2020-11-17
EP3212230A1 (en) 2017-09-06
BR112017008959A2 (pt) 2018-01-16
US20170333556A1 (en) 2017-11-23
HK1243328A1 (zh) 2018-07-13
ZA201702347B (en) 2021-07-28
SG10201913099YA (en) 2020-02-27
CY1124033T1 (el) 2022-05-27
PT3212230T (pt) 2021-04-19
CN107073118B (zh) 2022-03-01
SI3212230T1 (sl) 2021-08-31
US20170137528A1 (en) 2017-05-18
EP3831847A1 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EA201691582A1 (ru) Новые фармацевтические препараты
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201790630A1 (ru) Способы получения рибозидов
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
EA201691541A1 (ru) Новые анти-baff антитела
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
EA201591513A1 (ru) Терапевтическое применение антител к vegfr1 (варианты)
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
MX2017014396A (es) Tratamiento de mieloma multiple.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
EA202091925A3 (ru) Дозировка и введение нефукозилированных анти-cd40 антител

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent